Publications by authors named "C Beguelin"
Article Synopsis
- - Growing awareness of neoehrlichiosis, a tick-borne infection caused by the bacterium Neoehrlichia mikurensis, particularly affecting immunosuppressed individuals.
- - Symptoms commonly include persistent fever and vascular complications, complicating the clinical picture.
- - Diagnosis relies on targeted PCR testing, which can cause delays, but starting doxycycline treatment quickly usually resolves symptoms effectively.
Background: We evaluated long-term trajectories of circulating hepatitis B virus (HBV) RNA and hepatitis B core-related antigen (HBcrAg) in persons with and without hepatitis B surface antigen (HBsAg) loss during tenofovir therapy in the Swiss HIV Cohort Study.
Methods: We included 29 persons with HIV with HBsAg loss and 29 matched persons with HIV without HBsAg loss. We compared HBV RNA and HBcrAg decline and assessed the cumulative proportions with undetectable HBV RNA and HBcrAg levels during tenofovir therapy using Kaplan-Meier estimates.
Background: Antiretroviral therapy (ART)-related weight gain is of particular concern in people with HIV (PWH). Although weight gain was observed among PWH receiving tenofovir alafenamide (TAF), little is known about the potential reversibility after TAF discontinuation. We evaluated weight and metabolic changes 12 months after TAF discontinuation in the Swiss HIV Cohort Study.
View Article and Find Full Text PDFBackground And Aims: Treatment for chronic hepatitis C virus (HCV) infections changed dramatically in the last decade. We assessed changes in the prevalence of replicating HCV infection, treatment uptake and liver-related morbidity and mortality in persons with HIV (PWH) and hepatitis C in the Swiss HIV cohort study.
Methods: We included all cohort participants between 2002 and 2021.
Objectives: Improving the understanding of the patterns of quantitative hepatitis B surface antigen (qHBsAg) trajectories associated with HBsAg loss is important in light of novel anti-hepatitis B virus agents being developed. We evaluated long-term qHBsAg trajectories in persons with HIV and HBV during tenofovir-containing antiretroviral therapy in the Swiss HIV Cohort Study.
Methods: We included 29 participants with and 29 without HBsAg loss, defined as qHBsAg <0.